Kala Pharmaceuticals Stock (NASDAQ:KALA)


ForecastRevenueOwnershipFinancialsChart

Previous Close

$5.90

52W Range

$4.21 - $9.25

50D Avg

$6.40

200D Avg

$6.51

Market Cap

$27.29M

Avg Vol (3M)

$26.21K

Beta

-2.14

Div Yield

-

KALA Company Profile


Kala Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies using its proprietary mucus penetrating particles technology for the treatment of eye diseases. The company's product candidates include KPI-012, which is in clinical development stage for the treatment of persistent corneal epithelial defects; EYSUVIS for the short-term treatment of the signs and symptoms of dry eye disease; and INVELTYS, a topical twice-a-day ocular steroid for the treatment of post-operative inflammation and pain following ocular surgery. Its preclinical development products comprise KPI-287 that inhibits the vascular endothelial and platelet derived growth factors for the treatment of retinal diseases, including wet age-related macular degeneration, diabetic macular edema, and retinal vein occlusion; and selective glucocorticoid receptor modulators program, a novel class of compounds to regulate gene expression through the transrepression pathway while avoiding the transactivation pathway. The company was formerly known as Hanes Newco, Inc. and changed its name to Kala Pharmaceuticals, Inc. in December 2009. Kala Pharmaceuticals, Inc. was incorporated in 2009 and is headquartered in Watertown, Massachusetts.

Show More

Industry

Drug Manufacturers - Specialty & Generic

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

43

IPO Date

Jul 20, 2017

Website

KALA Performance


Revenue Breakdown


Revenue Breakdown by Product/Service

Product/ServiceSep 22Jun 22Mar 22
Sales discounts and contractual fee for service arrangements$20.00K$2.06M$1.54M

Fiscal year ends in Dec 23 | Currency in USD

KALA Financial Summary


Dec 23Dec 22Dec 21
Revenue-$3.89M$11.24M
Operating Income$-39.15M$-81.36M$-109.43M
Net Income$-42.20M$-223.00K$-152.30M
EBITDA$-38.85M$-81.62M$-107.04M
Basic EPS$-17.35$-0.15$-116.79
Diluted EPS$-17.35$-0.15$-115.68

Fiscal year ends in Dec 23 | Currency in USD

Latest Earnings Call Transcripts


Q2 22Aug 12, 22 | 7:51 PM
Q1 22May 16, 22 | 10:54 AM
Q4 21Mar 29, 22 | 12:10 PM

Peer Comparison


TickerCompany
BFRIBiofrontera Inc.
DVAXDynavax Technologies Corporation
NBIXNeurocrine Biosciences, Inc.
SHPHShuttle Pharmaceuticals Holdings, Inc.
DERMJourney Medical Corporation
AKANAkanda Corp.
ITCIIntra-Cellular Therapies, Inc.
LFCRLifecore Biomedical, Inc.
ORGOOrganogenesis Holdings Inc.
ALKSAlkermes plc